Vaxcyte, Inc.
PCVX
$34.54
$1.644.99%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -463.93M | -507.65M | -497.19M | -436.82M | -402.27M |
| Total Depreciation and Amortization | 15.85M | 14.01M | 12.00M | 10.92M | 10.17M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 50.35M | 37.95M | 27.89M | 16.97M | 13.99M |
| Change in Net Operating Assets | -54.90M | -14.35M | -9.57M | 715.00K | 81.32M |
| Cash from Operations | -452.63M | -470.04M | -466.88M | -408.22M | -296.79M |
| Capital Expenditure | -119.16M | -146.20M | -115.46M | -74.34M | -67.88M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1.89B | -1.32B | -407.67M | -701.94M | -705.43M |
| Cash from Investing | -2.01B | -1.46B | -523.13M | -776.28M | -773.31M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.46B | 2.46B | 986.66M | 1.42B | 643.69M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -14.29M | -13.54M | -6.81M | -6.46M | -3.88M |
| Cash from Financing | 2.45B | 2.45B | 979.85M | 1.42B | 639.81M |
| Foreign Exchange rate Adjustments | 426.00K | -8.61M | -1.98M | -647.00K | -6.69M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -9.36M | 505.27M | -12.13M | 231.29M | -436.97M |